The Alborada Drug Discovery Institute (ADDI) will collaborate with YD Global Life Science Co. Ltd. (YDGLS) to develop inhibitors of the unfolded protein response for the treatment of diseases that cause dementia.

G protein-coupled receptor 183 (GPR183/EBI2) is one of the key regulators of the innate immune system, and it has been shown to be upregulated in multiple sclerosis (MS) plaques. In a recently reported study, researchers from Medical University of Gdansk evaluated the effects of pharmacological modulation of GPR183 signaling on remyelination.

One way psychiatric disorders differ from neurological disorders is by the absence of anatomically defined neuropathology. “Alzheimer's disease, Parkinson's disease or stroke have a very clear picture of what cells are changing and how they're changing. The specific changes are very clear under a microscope, but in psychiatric diseases one hasn't been able to see that,” Daniel Geschwind told BioWorld.

Dimethylfumarate (DMF) is largely used for treating multiple sclerosis (MS), but about 61% of DMF-treated patients develop lymphopenia, with its consequent associated risks. Biomarkers for monitoring treatment efficacy with DMF in patients with MS would be helpful in this field.

Researchers from Bern University Hospital and University of Bern presented data from a case study that identified the presence of anti-neurochondrin antibodies as a potential biomarker of primary autoimmune cerebellar ataxia (PACA).